ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK)

HKD 5.36

(-1.83%)

Market Cap (In HKD)

2.04 Billion

Revenue (In HKD)

386 Thousand

Net Income (In HKD)

-379.45 Million

Avg. Volume

2.84 Million

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.21-31.0
PE
-
EPS
-
Beta Value
-0.15869868
ISIN
CNE100006624
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Tian Wenzhi
Employee Count
-
Website
https://www.immuneonco.com
Ipo Date
2023-09-05
Details
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, focuses on the development of immuno-oncology therapies. Its lead product candidate is IMM01, a clinical-stage CD47-targeted molecule for the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). It also develops IMM0306, a CD47×CD20 bispecific molecule for the treatment of R/R B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, a CD47×HER2 bispecific molecule for the treatment of HER2-positive and HER2-low expressing solid tumors; IMM2520, a CD47×PD-L1 bispecific molecule for the treatment of solid tumors; IMM47, a humanized monoclonal antibody targeting CD24 for cancer treatment; MM4701, a bispecific molecule that simultaneously targets CD47 and CD24; IMM2510, a bispecific molecule with a mAb-Trap structure targeting VEGF and PD-L1; IMM27M, a CTLA-4 antibody with enhanced ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody with enhanced ADCC activity. The company was founded in 2015 and is headquartered in Shanghai, China.